University of Birmingham to team up with Cobra Biologics under a KTP

Posted on Wednesday 13th February 2013

Knowledge Transfer Partnership award granted between the University of Birmingham and Cobra Biologics

Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals, with the University of Birmingham have been awarded a 3 year grant funded by the Biotechnology and Biological Sciences Research Council (BBSRC), Technology Strategy Board (TSB) and the Engineering and Physical Sciences Research Council (EPSRC) to develop innovative screening procedures for microbial expression systems and advanced fermentation processes for the production of novel therapeutic proteins.

The project will be led by Dr Tim Overton from the School of Chemical Engineering at the University of Birmingham, with input from Professor Jeff Cole from the School of Biosciences. The project builds on work performed at Birmingham funded by the BBSRC-EPSRC Bioprocess Research Industry Club (BRIC).

Peter Coleman CEO of Cobra Biologics said “Cobra is delighted to have been awarded this KTP grant with the University of Birmingham. Our customers expect us, as a Contract Manufacturing Organisation, to be able to provide cost effective and advanced production solutions in order for them to bring novel and ground breaking drugs to patients. We look forward to working with Dr Tim Overton and Prof Jeff Cole in continuing to develop our long term collaborations with the University of Birmingham into the field of microbial protein production”.”

About Knowledge Transfer Partnerships
Knowledge Transfer Partnerships is a UK-wide programme helping businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills that reside within the UK Knowledge Base.  

For more information about KTP at the University of Birmingham please contact: ktp@contacts.bham.ac.uk

About Cobra Biologics
Cobra Biologics is a leading international clinical and commercial manufacturer of biologics and pharmaceuticals with three GMP approved facilities. We offer a broad range of integrated and stand-alone development services, stretching from cell line development through to the supply of investigational medicinal products and commercial production. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop drugs for the benefit of patients. Cobra Biologics provides manufacturing solutions to the biologics and pharmaceutical industry covering antibodies, recombinant proteins, viruses, DNA, cellular therapeutics and small molecules.   

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com

About the University of Birmingham
1. The University of Birmingham is a truly vibrant, global community and an internationally-renowned institution. Ranked amongst the world’s top 100 institutions, its work brings people from across the world to Birmingham, including researchers and teachers and more than 4,000 international students from nearly 150 countries.

2. The University is home to nearly 30,000 students. With more than 7,500 postgraduate students from across the world, Birmingham is one of the most popular universities for postgraduate study in the UK.

3. The University plays an integral role in the economic, social and cultural growth of local and regional communities; working closely with businesses and organisations, employing approximately 6,000 staff and providing 10,000 graduates annually.

For more information on working with the University of Birmingham on collaborative projects please contact businessteam@bham.ac.uk

For media enquiries please contact Tim Yates on on +44 (0)121 414 8635 or email t.yates.1@bham.ac.uk